Literature DB >> 17189622

The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature.

Joanne L Favaloro1, Barbara K Kemp-Harper.   

Abstract

OBJECTIVE: The nitroxyl anion (HNO) is the one-electron reduction product of NO(). This redox variant has been shown to be endogenously produced and to have effects that are pharmacologically distinct from NO(). This study investigates the vasodilator and chronotropic effects of HNO in the rat isolated coronary vasculature.
METHODS: Sprague-Dawley rat hearts were retrogradely perfused with Krebs' solution (8 ml/min) using the Langendorff technique. Perfusion pressure was raised using a combination of infusion of phenylephrine and bolus additions of the thromboxane mimetic U46619 to attain a baseline perfusion pressure of 100-120 mm Hg. The vasodilator effects of a nitroxyl anion donor, Angeli's salt, were examined in the absence and presence of HNO and NO* scavengers, K+ channel inhibition, and soluble guanylate cyclase (sGC) inhibition. In addition, the inotropic and chronotropic effects of Angeli's salt were examined in hearts at resting perfusion pressure (50-60 mm Hg) and compared to responses evoked by acetylcholine and isoprenaline.
RESULTS: Angeli's salt causes a potent and reproducible vasodilatation in isolated perfused rat hearts. This response is unaffected by the NO* scavenger hydroxocobalamin (0.1 mM) but is significantly inhibited by the HNO scavenger N-acetyl-L-cysteine (4 mM), suggesting that HNO is the mediator of the observed responses. Vasodilatation responses to Angeli's salt were virtually abolished in the presence of the sGC inhibitor ODQ (10 microM). The magnitude of the vasodilatation response to Angeli's salt was significantly reduced in the presence of 30 mM K+, 10 microM glibenclamide and in the presence of the calcitonin gene-related peptide (CGRP) antagonist CGRP((8-37)) (0.1 microM). Angeli's salt had little effect on heart rate or force of contraction, whilst isoprenaline and acetylcholine elicited significant positive and negative cardiotropic effects, respectively.
CONCLUSIONS: The HNO donor Angeli's salt elicits a potent and reproducible vasodilatation response. The results suggest that the response is elicited by HNO through sGC-mediated CGRP release and K(ATP) channel activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17189622     DOI: 10.1016/j.cardiores.2006.11.018

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  45 in total

1.  A novel role for HNO in local and spreading vasodilatation in rat mesenteric resistance arteries.

Authors:  Kathryn H Yuill; Polina Yarova; Barbara K Kemp-Harper; Christopher J Garland; Kim A Dora
Journal:  Antioxid Redox Signal       Date:  2010-10-07       Impact factor: 8.401

Review 2.  Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways.

Authors:  Robert Y S Cheng; Debashree Basudhar; Lisa A Ridnour; Julie L Heinecke; Aparna H Kesarwala; Sharon Glynn; Christopher H Switzer; Stefan Ambs; Katrina M Miranda; David A Wink
Journal:  Nitric Oxide       Date:  2014-08-19       Impact factor: 4.427

Review 3.  The emergence of nitroxyl (HNO) as a pharmacological agent.

Authors:  Christopher H Switzer; Wilmarie Flores-Santana; Daniele Mancardi; Sonia Donzelli; Debashree Basudhar; Lisa A Ridnour; Katrina M Miranda; Jon M Fukuto; Nazareno Paolocci; David A Wink
Journal:  Biochim Biophys Acta       Date:  2009-05-06

4.  The shy Angeli and his elusive creature: the HNO route to vasodilation.

Authors:  Nazareno Paolocci; David A Wink
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

5.  Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674.

Authors:  Steve Lancel; Jingmei Zhang; Alicia Evangelista; Mario P Trucillo; Xiaoyong Tong; Deborah A Siwik; Richard A Cohen; Wilson S Colucci
Journal:  Circ Res       Date:  2009-03-05       Impact factor: 17.367

6.  Soluble guanylate cyclase is required for systemic vasodilation but not positive inotropy induced by nitroxyl in the mouse.

Authors:  Guangshuo Zhu; Dieter Groneberg; Gautam Sikka; Daijiro Hori; Mark J Ranek; Taishi Nakamura; Eiki Takimoto; Nazareno Paolocci; Dan E Berkowitz; Andreas Friebe; David A Kass
Journal:  Hypertension       Date:  2014-12-01       Impact factor: 10.190

Review 7.  A recent history of nitroxyl chemistry, pharmacology and therapeutic potential.

Authors:  Jon M Fukuto
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

Review 8.  Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure.

Authors:  Barbara K Kemp-Harper; John D Horowitz; Rebecca H Ritchie
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

9.  Dual mechanisms of HNO generation by a nitroxyl prodrug of the diazeniumdiolate (NONOate) class.

Authors:  Daniela Andrei; Debra J Salmon; Sonia Donzelli; Azadeh Wahab; John R Klose; Michael L Citro; Joseph E Saavedra; David A Wink; Katrina M Miranda; Larry K Keefer
Journal:  J Am Chem Soc       Date:  2010-10-29       Impact factor: 15.419

10.  The effects of nitroxyl (HNO) on soluble guanylate cyclase activity: interactions at ferrous heme and cysteine thiols.

Authors:  Thomas W Miller; Melisa M Cherney; Andrea J Lee; Nestor E Francoleon; Patrick J Farmer; S Bruce King; Adrian J Hobbs; Katrina M Miranda; Judith N Burstyn; Jon M Fukuto
Journal:  J Biol Chem       Date:  2009-06-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.